NASDAQ:CALC - Nasdaq - US38942Q2021 - Common Stock - Currency: USD
NASDAQ:CALC (2/21/2025, 8:05:04 PM)
2.35
-0.09 (-3.69%)
The current stock price of CALC is 2.35 USD. In the past month the price decreased by -18.69%. In the past year, price decreased by -47.66%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.62 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
CalciMedica, Inc. operates as a biopharmaceutical company. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2020-09-25. The firm's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The firm is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).
CALCIMEDICA INC
505 Coast Boulevard South, Suite 307
La Jolla CALIFORNIA US
Employees: 13
Company Website: https://calcimedica.com/
Investor Relations: https://ir.calcimedica.com/
Phone: 18589525500
The current stock price of CALC is 2.35 USD. The price decreased by -3.69% in the last trading session.
The exchange symbol of CALCIMEDICA INC is CALC and it is listed on the Nasdaq exchange.
CALC stock is listed on the Nasdaq exchange.
10 analysts have analysed CALC and the average price target is 16.32 USD. This implies a price increase of 594.47% is expected in the next year compared to the current price of 2.35. Check the CALCIMEDICA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CALCIMEDICA INC (CALC) has a market capitalization of 31.68M USD. This makes CALC a Nano Cap stock.
CALCIMEDICA INC (CALC) currently has 13 employees.
CALCIMEDICA INC (CALC) has a resistance level at 2.52. Check the full technical report for a detailed analysis of CALC support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CALC does not pay a dividend.
CALCIMEDICA INC (CALC) will report earnings on 2025-03-26, after the market close.
CALCIMEDICA INC (CALC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.08).
The outstanding short interest for CALCIMEDICA INC (CALC) is 0.65% of its float. Check the ownership tab for more information on the CALC short interest.
ChartMill assigns a fundamental rating of 2 / 10 to CALC. The financial health of CALC is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months CALC reported a non-GAAP Earnings per Share(EPS) of -1.08. The EPS increased by 94.81% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -83.81% | ||
ROE | -150.48% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 84% to CALC. The Buy consensus is the average rating of analysts ratings from 10 analysts.